ETR:SBS

Stratec (SBS) Stock Forecast, Price & News

€99.00

-0.20 (-0.20%)

(As of 05/25/2022 12:00 AM ET)

Add

Compare

Today's Range: €98.20
▼
€99.50
50-Day Range: €94.70
▼
€126.20
52-Week Range: €92.70
▼
€147.40

Volume: 2,745 shs
Average Volume: 6,253 shs
Market Capitalization: $1.20 billion

P/E Ratio: 30.46
Dividend Yield: 0.94%
Beta: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive SBS News and Ratings via Email

Sign-up to receive the latest news and ratings for Stratec and its competitors with MarketBeat's FREE daily newsletter.

About Stratec

Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.

May 20, 2022 | uk.finance.yahoo.com

STRATEC’S ANNUAL GENERAL MEETING APPROVES DIVIDEND INCREASE AND EXTENSION TO SUPERVISORY BOARD

May 20, 2022 | markets.businessinsider.com

DGAP-News: STRATECS ANNUAL GENERAL MEETING APPROVES DIVIDEND INCREASE AND EXTENSION TO SUPERVISORY BOARD

May 17, 2022 | americanbankingnews.com

Stratec (ETR:SBS) Given a €125.00 Price Target at Berenberg Bank

May 8, 2022 | americanbankingnews.com

Stratec (ETR:SBS) Given a €138.00 Price Target by Deutsche Bank Rese... Analysts

May 7, 2022 | americanbankingnews.com

Stratec (ETR:SBS) PT Set at €116.00 by Warburg Research

May 5, 2022 | markets.businessinsider.com

DGAP-News: STRATEC POSTS GOOD START TO YEAR AND FURTHER SALES GROWTH IN FIRST QUARTER OF 2022

March 30, 2022 | markets.businessinsider.com

DGAP-News: STRATEC SE: STRATEC GENERATES NEW RECORD SALES AND EARNINGS IN 2021 FINANCIAL YEAR

January 21, 2019 | finance.yahoo.com

Stratec SE (FRA:SBS) Has A ROE Of 10%

See More Headlines

Industry, Sector and Symbol

Stock Exchange: ETR
Industry: Medical Devices
Sub-Industry: N/A
Sector: Medical
Current Symbol: ETR:SBS
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: www.stratec.com
Phone: +49-7082-79160
Fax: N/A
Employees: 1,282
Year Founded: N/A

Sales & Book Value

Annual Sales: $290.73 million
Price / Sales: 4.13
Cash Flow: €4.11 per share
Price / Cash Flow: 24.08
Book Value: €17.94 per share
Price / Book: 5.52

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 39.46
Current Ratio: 4.49
Quick Ratio: 2.55

Price-To-Earnings

Trailing P/E Ratio: 30.46
Forward P/E Ratio: 25.58
P/E Growth: 6

Miscellaneous

Outstanding Shares: 12,126,100
Free Float: N/A
Market Cap: $1.20 billion
Optionable: Optionable

Company Calendar

Today: 5/26/2022
Next Earnings (Estimated): 8/05/2022

MarketRank^™

Overall MarketRank^™

1.45 out of 5 stars

2.0 Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of €134.40, Stratec has a forecasted upside of 35.8% from its current price of €99.00.
Amount of Analyst Coverage
Stratec has received no research coverage in the past 90 days.

4.4 Community Rank

Outperform Votes
Stratec has received 156 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Stratec has received 79 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Stratec has received 66.38% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Stratec and other stocks. Vote “Outperform” if you believe SBS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SBS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.8 Dividend Strength

Dividend Yield
Stratec has a dividend yield of 0.94%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Stratec does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Stratec is 29.23%. This payout ratio is at a healthy, sustainable level, below 75%.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Stratec insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Stratec is 30.46, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 9.87.
Price to Earnings Ratio vs. Sector
The P/E ratio of Stratec is 30.46, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 13.01.
Price to Earnings Growth Ratio
Stratec has a PEG Ratio of 6.00. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Stratec has a P/B Ratio of 5.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Stratec (ETR:SBS) Frequently Asked Questions

When is Stratec's next earnings date?: Stratec is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022.
View our earnings forecast for Stratec.
Is Stratec a good dividend stock?: Stratec pays an annual dividend of €0.95 per share and currently has a dividend yield of 0.94%. The dividend payout ratio of Stratec is 29.23%. This payout ratio is at a healthy, sustainable level, below 75%.
What price target have analysts set for SBS?: 0 analysts have issued 12 month price objectives for Stratec's shares. Their forecasts range from €116.00 to €154.00. On average, they anticipate Stratec's share price to reach €134.40 in the next twelve months. This suggests a possible upside of 35.8% from the stock's current price.
View analysts' price targets for Stratec or view top-rated stocks among Wall Street analysts.
Who are Stratec's key executives?: Stratec's management team includes the following people:
Mr. Marcus Wolfinger, Chairman of Board of Management & CEO (Age 55, Pay $707k)
Dr. Robert Siegle, Director of Fin. & HR and Member of Board of Management (Age 55, Pay $566k)
Dr. Claus Vielsack, Director of Product Devel. & Member of Board of Management (Age 55, Pay $484k)
Mr. Hermann Leistner, Founder & Advisor (Age 76)
Mr. Jan Keppeler, Head of Investor Relations & Corp. Communications
Mr. Andre Loy, Director of Corp. Communications
Mr. Roland Utz, Head of Supply Chain Management & Sr. VP
Who are some of Stratec's key competitors?: Some companies that are related to Stratec include ConvaTec Group (CTEC), Butterfly Network (BFLY), Drägerwerk AG & Co. KGaA (DRW3), Avacta Group (AVCT), Viemed Healthcare (VMD), Protech Home Medical (PTQ), Hamilton Thorne (HTL), Medica Group (MGP), Viemed Healthcare (VMD), Creo Medical (CREO), Polarean Imaging (POLX), Advanced Oncotherapy (AVO), Asensus Surgical (ASXC), MRI Interventions (MRIC) and Inspiration Healthcare Group (IHC).
View all of SBS's competitors.
What other stocks do shareholders of Stratec own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Stratec investors own include Great Portland Estates (GPOR), Gogo (GOGO), Depomed (DEPO), Cenovus Energy (CVE), China Hydroelectric Corp Foreign (CHC), Bio-Rad Laboratories (BIO), Berkshire Hills Bancorp (BHLB), ASGN (ASGN), Apptio (APTI) and Anadarko Petroleum (APC).
What is Stratec's stock symbol?: Stratec trades on the ETR under the ticker symbol "SBS."
What is Stratec's stock price today?: One share of SBS stock can currently be purchased for approximately €99.00.
How much money does Stratec make?: Stratec has a market capitalization of $1.20 billion and generates $290.73 million in revenue each year.
How many employees does Stratec have?: Stratec employs 1,282 workers across the globe.
What is Stratec's official website?: The official website for Stratec is www.stratec.com.
How can I contact Stratec?: Stratec's mailing address is Gewerbestr. 37, BIRKENFELD, 75217, Germany. The company can be reached via phone at +49-7082-79160.

This page was last updated on 5/26/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.